Analyst Price Targets — AUTL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 18, 2024 11:08 am | Graig Suvannavejh | Goldman Sachs | $7.60 | $3.03 | StreetInsider | Goldman Sachs Upgrades Autolus Therapeutics plc (AUTL) to Buy |
| May 20, 2024 6:43 am | Yanan Zhu | Wells Fargo | $8.00 | $4.39 | StreetInsider | Wells Fargo Reiterates Overweight Rating on Autolus Therapeutics plc (AUTL) |
| April 8, 2024 12:28 pm | Asthika Goonewardene | Truist Financial | $11.00 | $5.53 | StreetInsider | Autolus Therapeutics plc (AUTL) PT Raised to $11 at Truist Securities |
| March 15, 2024 8:28 am | Asthika Goonewardene | Truist Financial | $10.00 | $5.82 | StreetInsider | Autolus Therapeutics plc (AUTL) PT Raised to $10 at Truist Securities |
Latest News for AUTL
Autolus Therapeutics (NASDAQ: AUTL) hosted an investor event focused on its acute lymphoblastic leukemia (ALL) program, featuring clinicians and investigators who discussed the treatment landscape, real-world experience with the company's CD19-directed CAR T-cell therapy obe-cel, and ongoing efforts to evaluate the product earlier in treatment and in pediatric patients. Adult relapsed/refractory ALL: unmet need and…
Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript
LONDON and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will participate in two upcoming investor conferences.
Autolus Therapeutics plc maintains a Hold rating due to a challenging risk/reward profile despite strong clinical data for Aucatzyl in r/r B-ALL. 2026 guidance targets $120–$135m in product revenues and a shift to positive gross margin, with AUTL's cash runway projected into Q4 2027. Key catalysts include pediatric ALL Phase 2 data (2027) and initial MS autoimmune data (late 2026), both with significant upside…
Autolus Therapeutics plc (AUTL) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AUTL.
U.S. House Trading
No House trades found for AUTL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.